Related Experiment Video
Updated: Jun 14, 2025
08:39
Culture of Bladder Cancer Organoids as Precision Medicine Tools
Published on: December 28, 2021
4.6K
Reducing financial toxicity in bladder cancer care.
Jeremy A Kurnot1, Deborah R Kaye1,2,3,4
1Department of Urology.
Current Opinion in Urology
|September 2, 2024
Summary
Bladder cancer treatment is costly, leading to financial toxicity that harms patients. Strategies like cost communication and financial navigators can help reduce this burden.
Area of Science:
- Oncology
- Health Economics
- Patient Advocacy
Background:
- Bladder cancer is the most expensive malignancy per patient.
- Financial toxicity, defined as adverse effects of treatment costs on quality of life, is linked to poorer outcomes.
Purpose of the Study:
- To discuss factors contributing to financial toxicity in bladder cancer patients.
- To identify populations at risk.
- To review strategies for mitigating financial burden.
Main Methods:
- Review of current literature on bladder cancer treatment costs.
- Analysis of novel therapies and their potential cost implications.
- Identification of existing and potential cost-reduction strategies.
Main Results:
- Bladder cancer treatment costs are rising with novel therapies.
- Potential cost-saving strategies include blue light cystoscopy, intravesical gemcitabine-docetaxel, home BCG therapy, and optimized surveillance.
- Clinicians can reduce financial burden through awareness, screening, cost communication, and referral to financial navigators, though these are underutilized.
Conclusions:
- Financial toxicity is a significant issue for bladder cancer patients, exacerbated by rising costs.
- Novel treatments may reduce financial toxicity.
- Current underutilized strategies like awareness, screening, cost discussions, and financial navigator referrals are crucial for reducing patient financial burden.
